A tool to predict racemization could help prevent drug discovery dead ends
Roisin McGuigan |
Many drugs are chiral molecules, which means that they have the potential to “flip” and exist as different enantiomers – non-superimposable mirror images of the original molecule with an identical chemical structure. In some cases, this flipping behavior can occur when an enantiomerically pure drug enters the body – a process known as racemization. Recent research aims to predict racemization (1), so we spoke to co-author Niek Buurma from Cardiff University’s School of Chemistry to discover more about the dangers of mirror molecules – and a new tool to remedy the problem.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!